Skip to content

The clinical study of treating diabetic kidney disease with Jiedu Tongluo Baoshen Formula in real world was evaluated based on propensity score matching method

The clinical study of treating diabetic kidney disease with Jiedu Tongluo Baoshen Formula in real world was evaluated based on propensity score matching method

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025001736
Enrollment
Unknown
Registered
2025-09-15
Start date
2025-09-17
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

Control group:Western basic treatment
Treatment group:Western basic treatment combined with Jiudu Tongluo Baoshen Formula

Sponsors

The Affiliated Hospital to Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) The patient's age is over 18 years old and the clinical diagnosis is DKD (stage III stage A2-A3); (2) Have received more than one month of basic Western medical treatment alone or a combination of traditional Chinese and Western medicine mainly based on Jiudu Tongluo Baoshen Formula; (3) Patients with complete basic information current illness history four diagnostic methods TCM syndromes and theories methods prescriptions and medicines; (4) Those who have no significant changes in diet and exercise during the period of taking the medicine.

Exclusion criteria

Exclusion criteria: (1)Proteinuria caused by non-diabetic nephropathy such as gout essential hypertension heart failure urinary tract infection ketoacidosis tumors and chronic kidney disease; (2) There are serious complications of the heart liver kidneys etc. or combined with other serious diseases; (3) Cases with incomplete basic information and laboratory tests; Those who meet any of the above conditions will be excluded.

Design outcomes

Primary

MeasureTime frame
UACR;Glomerular Filtration Rate;

Secondary

MeasureTime frame
Triglyceride;Glutamic-pyruvic transaminase;ß2-microglobulin;Glutamic oxalacetic transaminase;Low-density lipoprotein cholesterol;Total Cholesterol;Blood Urea Nitrogen;High-density Lipoprotein Cholesterol;Cystatin C;Fasting Blood Glucose;Glycosylated Hemoglobin;Serum Creatinine;

Countries

China

Contacts

Public ContactGuanchi Yan

The Affiliated Hospital to Changchun University of Chinese Medicine

372198682@qq.com17519452254

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026